Trial Profile
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine IMA202-101)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs IMA-202 (Primary) ; Interleukin-2
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine; ACTengine IMA202-101
- Sponsors Immatics US
- 27 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2022 According to an Immatics media release, patient recruitment in the dose escalation part of the Phase 1 trial has been completed and dose escalation is ongoing.